Company Encyclopedia
View More
name
Furui Co., Ltd
300049.SZ
Inner Mongolia Furui Medical Science Co., Ltd. engages in the production and sale of pharmaceutical drugs in China and internationally. The company operates in two segments: pharmaceutical production and sales; and diagnostic equipment R&D, production and sales. The pharmaceutical production and sales segment produces and sells products, such as Fufang Biejiaruangan tablets and shell fat capsules.
3.157 T
300049.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking16/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.02%C
    • Profit Margin8.38%B
    • Gross Margin75.24%A
  • Growth ScoreB
    • Revenue YoY10.83%B
    • Net Profit YoY-5.55%C
    • Total Assets YoY13.71%B
    • Net Assets YoY21.76%A
  • Cash ScoreB
    • Cash Flow Margin1193.64%B
    • OCF YoY10.83%B
  • Operating ScoreC
    • Turnover0.49C
  • Debt ScoreB
    • Gearing Ratio26.94%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Caitong Securities: The demand for phosphonamide monomers will flourish, and multinational pharmaceutical companies' supply chain enterprises are expected to benefit

    Caitong Securities released a research report indicating that phosphoramidite monomers play a key role in the development of small nucleic acid drugs, and demand is expected to grow significantly in the future. According to predictions from sphericalinsights, global sales of nucleotides will reach USD 730 million in 2023, with China being the largest production market, primarily focused on exports. Small nucleic acid drugs are considered potential treatment options for various diseases due to their unique molecular structure and therapeutic mechanisms, and companies within the supply chains of multinational pharmaceutical companies are expected to benefit from this

    Zhitong·
    SH
    688566
    +0.55%
    SH
    688136
    +0.21%
    SZ
    002250
    +0.92%
    Zhitong·
    SH
    688566
    +0.55%
    SH
    688136
    +0.21%
    SZ
    002250
    +0.92%

    Furui Co., Ltd: Net profit in the third quarter was 59.9522 million yuan, a year-on-year increase of 125.06%

    Furui Co., Ltd. announced that the revenue for the third quarter was 388 million yuan, a year-on-year increase of 14.94%; the net profit was 59.9522 million yuan, a year-on-year increase of 125.06%. The revenue for the first three quarters was 1.101 billion yuan, a year-on-year increase of 12.37%; the net profit was 112 million yuan, a year-on-year increase of 9.69%

    Zhitong·
    SZ
    300049
    +7.09%
    Zhitong·
    SZ
    300049
    +7.09%

    Furui Co., Ltd. released its performance for the first half of the year, with a net profit attributable to the parent company of 51.934 million yuan, a decrease of 31.09%

    According to the Zhitong Finance APP, Furui Co., Ltd. released its semi-annual report for 2025, reporting an operating income of 713 million yuan, a year-on-year increase of 11.02%. The net profit attributable to shareholders of the listed company was 51.934 million yuan, a year-on-year decrease of 31.09%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 53.323 million yuan, a year-on-year decrease of 28.39%. The basic earnings per share were 0.1972 yuan

    Zhitong·
    SZ
    300049
    +7.09%
    Zhitong·
    SZ
    300049
    +7.09%

    The concept of innovative drugs is active again, Shen Lian Biomedical has achieved a two-day limit up

    In the morning session, the innovative drug concept became active again, with Shen Lian Biomedical hitting a two-day limit-up, Furui Co., Ltd. reaching a 20% limit-up, and HYBIO, Sun-Novo, SHANGHAI YIZHONG, and Sunshine Guojian Pharmaceutical rising over 5%. According to news, the "China Innovative Drug and Medical Device Multi-Payment White Paper" shows that the estimated scale of China's innovative drug and medical device market in 2024 is about 162 billion yuan. The white paper predicts that by 2035, the market size of innovative drugs and medical devices in China will exceed 1 trillion yuan

    Zhitong·
    SH
    688336
    -0.52%
    SH
    688098
    +0.76%
    SZ
    300049
    +7.09%
    Zhitong·
    SH
    688336
    -0.52%
    SH
    688098
    +0.76%
    SZ
    300049
    +7.09%

    Furui Co., Ltd. released its 2024 annual performance, with a net profit attributable to the parent company of 113 million yuan, an increase of 11.54%

    According to the Zhitong Finance APP, Furui Co., Ltd. released its 2024 annual report, showing an operating income of 1.349 billion yuan, a year-on-year increase of 16.93%. The net profit attributable to shareholders of the listed company was 113 million yuan, a year-on-year increase of 11.54%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 118 million yuan, a year-on-year increase of 19.33%. The basic earnings per share were 0.4285 yuan

    Zhitong·
    SZ
    300049
    +7.09%
    Zhitong·
    SZ
    300049
    +7.09%
    © 2025 Longbridge｜Disclaimer